LE
LENZ.US LENZ Therapeutics Inc
- Market cap
- USD 130M
- P/E
- -
- P/B
- 0.68x
- ROE
- -72.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LENZ.US undervalued?
Graham numberThe Graham number of LENZ Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LENZ Therapeutics Inc fundamental analysis
No fundamental analysis for LENZ Therapeutics Inc yet.
LENZ Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, Calif…
Full company profileLENZ Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LENZ Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | - | 0.00 | 15.0M | 0.00 | 0.00 | 19.1M | 14.4M |
| Gross Profit | - | -121K | -734K | 15.0M | -2.41M | -58.0K | 18.4M | 11.8M |
| Operating Income | -29.0K | -13.5M | -60.4M | -10.5M | -72.4M | -58.6M | -91.1M | -148M |
| EBITDA | 143K | -68.2M | -70.0M | -10.5M | -70.1M | -49.7M | -81.3M | -141M |
| Net Income | -109K | -68.4M | -70.8M | -10.8M | -70.0M | -49.8M | -82.1M | -139M |
| EPS | -0.01 | -8.24 | -8.54 | -1.38 | -8.59 | -2.34 | -2.85 | -4.43 |
| Balance Sheet | ||||||||
| Total Assets | 6.00K | 22.6M | 18.3M | 47.0M | 70.4M | 215M | 306M | 210M |
| Total Liabilities | 2.22M | 32.4M | 32.5M | 71.1M | 163M | 11.2M | 21.5M | 17.8M |
| Shareholders' Equity | -2.22M | -9.80M | -14.2M | -24.2M | -92.7M | 204M | 284M | 192M |
| Cash & Short-term Investments | 6.00K | 19.8M | 18.3M | 44.4M | 65.8M | 209M | 292M | 197M |
| Total Debt | 2.21M | - | - | 250K | 329K | 1.38M | 815K | 460K |
| Cash Flow | ||||||||
| Operating Cash Flow | -19.0K | -8.72M | -52.9M | -88.0M | -60.4M | -59.4M | -69.2M | -126M |
| Capital Expenditure | 0.00 | 1.55M | 5.74M | 6.59M | 30.0K | 468K | 827K | 45.3K |
| Free Cash Flow | -19.0K | -10.3M | -58.6M | -94.6M | -60.4M | -59.9M | -70.0M | -126M |
| Ratios | ||||||||
| ROE | - | - | - | - | - | -24.4% | -28.9% | -72.5% |
| ROA | -1,816.7% | -303.0% | -385.9% | -23.0% | -99.4% | -23.1% | -26.8% | -66.3% |
| Net Profit Margin | - | - | - | -72.1% | - | - | -430.3% | -969.0% |
| Debt to Equity | - | - | - | - | - | 0.01x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
LENZ Therapeutics Inc dividends
LENZ Therapeutics Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:7 on Mar 22, 2024.
Who owns LENZ Therapeutics Inc
- Insiders 2.98%
- Institutions 91.27%
- Public & others 5.75%
- Shares outstanding 31.4M
- Free float 22.2M
Top funds holding LENZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 820K | 2.61% | 0.00% | Sep 2026 |
| Fidelity Growth Company Fund | 811K | 2.58% | -8.83% | Aug 2026 |
| C WorldWide Healthcare Select 1A | 700K | 2.23% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 527K | 1.68% | 0.00% | Oct 2026 |
| PRIMECAP Odyssey Aggressive Growth | 406K | 1.29% | 0.00% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 254K | 0.81% | +0.27% | Oct 2026 |
| Fidelity Small Cap Index | 242K | 0.77% | +7.31% | Aug 2026 |
| iShares Biotechnology ETF | 213K | 0.68% | -0.19% | Oct 2026 |
| iShares Russell 2000 Value ETF | 172K | 0.55% | 0.00% | Oct 2026 |
| A4Investments SICAV SIF ACCI IlanaA2EURH | 170K | 0.54% | +41.67% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 168K | 0.53% | +826.11% | Sep 2026 |
| Fidelity Extended Market Index | 122K | 0.39% | +25.09% | Sep 2026 |
| Vanguard Russell 2000 ETF | 119K | 0.38% | +0.43% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 118K | 0.37% | +0.22% | Oct 2026 |
| Bridge Builder Small Cap Fund | 91.5K | 0.29% | 0.00% | Oct 2026 |
| Strategic Advisers U.S. Total Stock | 82.2K | 0.26% | +103.57% | Sep 2026 |
| BlackRock Advantage SMID Cap Instl | 73.3K | 0.23% | +57.95% | Sep 2026 |
| Vanguard US Opportunities Ins USD Acc | 65.8K | 0.21% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 62.6K | 0.20% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 57.5K | 0.18% | +0.11% | Sep 2026 |
Top institutions holding LENZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 4.18M | 13.30% | 0.00% | Jun 2026 |
| Alpha Wave Global LP | 3.61M | 11.50% | 0.00% | Jun 2026 |
| FMR Inc | 3.56M | 11.33% | -1.08% | Jun 2026 |
| Versant Venture Management LLC | 2.66M | 8.46% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.29M | 7.30% | +15.95% | Jun 2026 |
| Squarepoint Ops LLC | 1.75M | 5.56% | +15.97% | Jun 2026 |
| Millennium Management LLC | 1.51M | 4.80% | +73.54% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.10M | 3.49% | +5.43% | Jun 2026 |
| 72 Investment Holdings, LLC | 1.02M | 3.24% | 0.00% | Jun 2026 |
| Blue Owl Capital Holdings LP | 757K | 2.41% | +49.34% | Jun 2026 |
| CAM Group Holding A/S | 700K | 2.23% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 565K | 1.80% | +7.64% | Jun 2026 |
| Trexquant Investment LP | 498K | 1.58% | +132.05% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 493K | 1.57% | +207.68% | Jun 2026 |
| Qube Research & Technologies | 482K | 1.53% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 473K | 1.51% | -27.10% | Jun 2026 |
| PRIMECAP Management Company | 472K | 1.50% | 0.00% | Sep 2026 |
| TANG CAPITAL MANAGEMENT LLC | 451K | 1.44% | 0.00% | Jun 2026 |
| Alyeska Investment Group, L.P. | 439K | 1.40% | -5.31% | Jun 2026 |
| State Street Corp | 407K | 1.29% | +1.11% | Jun 2026 |
LENZ Therapeutics Inc company profile
- Company name
- LENZ Therapeutics Inc
- Ticker
- LENZ.US
- Exchange
- USA Stocks
- Listed since
- Jun 25, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 40
- Fiscal year end
- December
- Address
- 201 Lomas Santa Fe Drive, Solana Beach, CA, United States, 92075
- Phone
- 858 925 7000
- Website
- lenz-tx.com
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
LENZ Therapeutics Inc management
9- Mr. Evert B. SchimmelpenninkPresident, CEO, Secretary & Director · born 1972
- Mr. James W. McCollumCo-Founder & Director · born 1955
- Mr. Shawn OlssonChief Commercial Officer · born 1983
- Mr. Marc G. Odrich M.D.Chief Medical Officer · born 1959
- Mr. Daniel R. Chevallard CPACFO, Principal Financial & Accounting Officer · born 1979
- Mr. Domenick PorfidiaVice President of Sales
- Mr. David ChoromanskiVice President of Marketing
- Ms. Melissa RosnessSenior Vice President of Manufacturing Operations
- Kris GambelinSenior Vice President of Regulatory & Clincal Operations